HIGHLIGHTS
- who: Katharigatta N. Venugopala from the Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Technology, Durban, South Africa have published the article: Targeting the DNA Damage Response Machinery for Lung Cancer Treatment, in the Journal: Pharmaceuticals 2022, 1475 of 27/Nov/2022
- what: A study was conducted to investigate the subcellular distribution of AKT1 in NSCLC cell lines following IR and stimulation using HER ligands. This study investigated the efficacy and potency of a combination therapy Veliparib/Talazoparib and radiotherapy, and showed that Talazoparib exerted a more additive effects in_vitro when given . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.